Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-11-2008 | Focus on...

FDG-PET in gynaecological cancers: recent observations

Author: Giovanni Lucignani

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2008

Excerpt

Of the various gynaecological neoplasms, endometrial, cervical and ovarian cancer give the most cause for concern, both epidemiologically and in terms of the evolution of the pathology. Whilst prevention remains the main strategy to reduce cancer incidences, imaging is central to work-up and appropriate management of patients after diagnosis. …

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74–108.PubMedCrossRef

Stroup AM, Harlan LC, Trimble EL. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol Oncol 2008;108(3):577–83.PubMedCrossRef

Iyer RB, Balachandran A, Devine CE. PET/CT and cross sectional imaging of gynecologic malignancy. Cancer Imaging 2007;7(Spec No A):S130–8.PubMedCrossRef

Huang CM. Human papillomavirus and vaccination. Mayo Clin Proc 2008;83(6):701–6.PubMed

Downs LS, Smith JS, Scarinci I, Flowers L, Parham G. The disparity of cervical cancer in diverse populations. Gynecol Oncol 2008;109(2 Suppl):S22–30.PubMedCrossRef

Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007;106(1):29–34.PubMedCrossRef

Yen TC, See LC, Lai CH, Tsai CS, Chao A, Hsueh S, et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging 2008;35(3):493–501.PubMedCrossRef

Bjurberg M, Kjellén E, Ohlsson T, Ridderheim M, Brun E. FDG-PET in cervical cancer: staging, re-staging and follow-up. Acta Obstet Gynecol Scand 2007;86(11):1385–91.PubMedCrossRef

Boughanim M, Leboulleux S, Rey A, Pham CT, Zafrani Y, Duvillard P, et al. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [¹⁸F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol 2008;26(15):2558–61.PubMedCrossRef

10.

Yildirim Y, Sehirali S, Avci ME, Yilmaz C, Ertopcu K, Tinar S, et al. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings. Gynecol Oncol 2008;108(1):154–9.PubMedCrossRef

11.

Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Sugimura K. Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol. 2008 doi:10.1007/s00330-008-0979-9

12.

Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111(2 Pt 1):436–47.PubMed

13.

Suzuki R, Miyagi E, Takahashi N, Sukegawa A, Suzuki A, Koike I, et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer 2007;17(4):890–6.PubMedCrossRef

14.

Kitajima K, Murakami K, Yamasaki E, Hagiwara S, Fukasawa I, Inaba N, et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Ann Nucl Med 2008;22(2):103–9.PubMedCrossRef

15.

Park JY, Kim EN, Kim DY, Suh DS, Kim JH, Kim YM, et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol 2008;108(3):486–92.PubMedCrossRef

16.

Kitajima K, Murakami K, Yamasaki E, Fukasawa I, Inaba N, Kaji Y, et al. Accuracy of ¹⁸F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol 2008;190(6):1652–8.PubMedCrossRef

17.

Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 2008;11(3–4):301–21.PubMed

18.

Sebastian S, Lee SI, Horowitz NS, Scott JA, Fischman AJ, Simeone JF, et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 2008;33(1):112–8.PubMedCrossRef

19.

Soussan M, Wartski M, Cherel P, Fourme E, Goupil A, Le Stanc E, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 2008;108(1):160–5.PubMedCrossRef

20.

Kim CK, Park BK, Choi JY, Kim BG, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr 2007;31(6):868–75.PubMed

21.

Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Fukasawa I, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 2008;35(8):1439–48.PubMedCrossRef

Title: FDG-PET in gynaecological cancers: recent observations
Author: Giovanni Lucignani
Publication date: 01-11-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0929-4

At a glance: The STEP trials

Springer Medicine

FDG-PET in gynaecological cancers: recent observations

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2008

The new EANM paediatric dosage card: additional notes with respect to F-18

Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment

FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis

11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma

Prognostic value of sympathetic innervation and cardiac asynchrony in dilated cardiomyopathy

Cardiac sympathetic nerve abnormality predicts ventricular tachyarrhythmic events in patients without conventional risk of sudden death